The company generates its revenue in three ways: product sales, development activities, and royalties. AstraZeneca and Teva entered into a settlement and license agreement pursuant to which AstraZeneca granted Teva a license to manufacture and commercialize the generic version of BYETTA® described in Teva’s ANDA. According to Teva, the Public Assessment Report for the decentralized procedure has been published and the product was filed in 17 countries, which addresses the majority of the market value in Europe. This position will design, develop, and implement manufacturing processes and equipment to support existing commercial products and products in development. Partnering with Antares; Devices; For Investors. Antares reported licensin… Antares development partner Teva, launched Teriparatide … Antares Pharma, Inc. (ATRS) is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Antares Pharma's other combination product development projects in collaboration with Teva include a multi-dose pen for a generic form of BYETTA® (exenatide injection) for the treatment of diabetes, and another multi-dose pen for a generic form of Forteo® (teriparatide [rDNA origin] injection) for the treatment of osteoporosis. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. You can change your choices at any time by visiting Your Privacy Controls. Our accurate detection technologies optimize efficiency by ensuring genuine reliability of all packaging and production processes, for guaranteed end user safety within the pharmaceutical industry. The company market and sell its proprietary product OTREXUP® (methotrexate) injection, which was launched in the U.S. in February 2014. The company's testosterone injection Xyosted and chemotherapy Otrexup both delivered strong sales growth. Antares Pharma’s FDA-approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP… PCI Pharma Services is an integrated full-service provider and a trusted partner to leading companies in the global healthcare industry. POSITION SUMMARY . Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. Our wide selection of fully customizable Inspection solutions for pharma can guarantee the consistent quality of your product. Antares' partnered product sales to Teva Pharmaceutical Industries, AMAG Pharmaceuticals, and Ferring Pharmaceuticals also increased year over year. Sumatriptan Injection USP (generic equivalent to Imitrex® STATdose Pen®). The company also make reusable, needle-free injection devices that administer injectable drugs, which are currently marketed primarily through its partner Ferring, for use with human growth hormone, and have two gel-based products that are commercialized through its partners pursuant to licensing arrangements. In 2001 Dr. Sadowski became Vice President of the Company’s Devices Group where he led the conceptualization and development of the VIBEX mini-needle injection technology platform. : +39-030-7283500 / Fax. As the natural choice for the most demanding industries , Antares Vision is more than a technology provider. Antares Pharma is developing XYOSTEDTM (testosterone enanthate) injection for testosterone replacement therapy, and submitted a 505 (b) (2) New Drug Application (“NDA”) to the FDA in December 2016. Customer service, documentation, purchase orders, general office, accounting, and the R&D facility. To date, Antares Pharma has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP®. The study included a screening phase, a treatment titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. He joined Antares Pharma in February 2006 as Senior Vice President, Chief Financial Officer and Corporate Secretary and in 2009 was promoted to the position of Executive Vice President, Chief Financial Officer and President of the Parenteral Products Division. OTREXUP® is the first FDA-approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector, indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Under a license, development and supply agreement, AMAG is responsible for the clinical development and preparation, submission and maintenance of all regulatory applications, the manufacture and supply of the drug, and the marketing, sale and distribution of the product. 877-870-0159 info@tpgs.com Our marketed products include Otrexup™, Sumatriptan autoinjector, Zoma-Jet and Gelnique, and are built on our proven auto injector and pen device platforms. Find out more about how we use your information in our Privacy Policy and Cookie Policy. About Antares Pharma. The settlement allows Teva to commercialize their exenatide product in the U.S. beginning October 15, 2017 or earlier under certain circumstances. With its commercialization partner Teva, the company launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference. The pages created by the user or by XWiki extensions on behalf of the user. Antares' product sales in Q4 of $28.5 million set an all-time high, and more than doubled the $14.2 million in the prior-year period. EWING - Antares Pharma, Inc. (NASDAQ: ATRS) ('the Company'), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held on December 1-3, 2020. Antares Pharma is collaborating with Teva on a VIBEX® auto injector pen containing epinephrine used for the treatment of severe allergic reactions (anaphylaxis). Antares Vision leads the complete process of protecting products throughout their life-cycle by delivering the most comprehensive solutions in Track & Trace, Inspection and Smart Data Management. Antares now offers three grades of TPGS: Food Grade, NF Grade and SF (non-GMO) Grade. 05 Nov 2020 Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results Read More. We and our partners will store and/or access information on your device through the use of cookies and similar technologies, to display personalised ads and content, for ad and content measurement, audience insights and product development. Contact us at Antares Health Products Vitamin E TPGS. In response to Teva’s paragraph IV certification contained in Teva’s ANDA for teriparatide, Eli Lilly & Co (“Lilly”) filed a lawsuit against Teva alleging infringement of six U.S. patents related to Forteo® (teriparatide [rDNA origin] injection) resulting in a 30-month stay in FDA approval of the ANDA. Information about your device and internet connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps. © 2020 ANTARES VISION S.p.A. - Via Del Ferro, 16 - 25039 Travagliato - Brescia - ITALY Tel. The NDA submission was accepted for standard review by the FDA and assigned a Prescription Drug User Fee Act (“PDUFA”) target date for completion of its review by October 20, 2017. FIRST COMMERCIAL PRODUCT USING ANTARES PHARMA'S MULTI-DOSE PEN PLATFORM LAUNCHES IN EUROPE EWING, NJ, July 21, 2020--Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") ("the Company"), a pharmaceutical technology company, announced the first commercialization of the Company's multi- dose pen platform launched in Europe. Antares Pharma continues to build its commercial portfolio, with four products approved by the FDA in less than 5 years, focusing on innovative, patient-focused therapeutic options. Manufacturing Engineer II. The company received FDA approval of its Abbreviated New Drug Application (“ANDA”) for 4 mg/0.5 mL and 6 mg/0.5 mL single-dose prefilled syringe auto-injectors, a generic equivalent to Imitrex® STATdose Pen®, in December 2015. To date, Antares Pharma has received FDA approval for dosage strengths of 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg and 25 mg of OTREXUP®. Antares Pharma’s FDA approved products include XYOSTED ® (testosterone enanthate) injection, OTREXUP ® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP… Teva submitted an amendment to the VIBEX® epinephrine pen ANDA in December 2014 and received a Complete Response Letter (“CRL”) from the FDA in February 2016 in which, according to Teva, the FDA identified certain major deficiencies. Dr. Sadowski joined Medi-Ject Corporation, a predecessor company to Antares Pharma, in March 1994 as Vice President, Product Development. Antares Vision performs in-line inspection to prevent cross-contamination and detect product defects during the phase of bottles filling with tablets and capsules. Antares Pharma has strategic alliances and partnership arrangements with several pharmaceutic companies. Antares Pharma’s FDA approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This press release contains forward-looking statements within the meaning of the safe … Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Teva also successfully concluded a decentralized procedure registration process in Europe. Includes modified extension pages (usually configuration pages). Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products … Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. AMAG submitted its sNDA for the Makena® subcutaneous auto injector in April 2017, which was accepted by the FDA and given a PDUFA target action date of February 14, 2018. Based upon a written response the company received from the FDA related to its clinical development program for XYOSTEDTM, the company conducted an additional supplemental safety study QST-15-005. The stay will expire in August 2018 unless the litigation is resolved sooner. In partnership with AMAG, Antares Pharma is currently developing a variation of its VIBEX® QuickShot® subcutaneous auto injector for use with AMAG’s Makena® (hydroxyprogesterone caproate injection) for the treatment of pre-term birth. TPGS has utility and a proven record of safety and efficacy in pharmaceutical, dietary supplement, food & beverage, personal care, animal nutrition and CBD and other botanical oil products. Antares Pharma has a portfolio of proprietary and partnered products, including approved commercial products and several product candidates in advanced stages of development and under active FDA review. With its commercialization partner Teva, the company launched Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults, in June 2016. Antares Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. In September 2016, the company announced the successful completion of the QST-15-005 study. ATRS. The company’s revenue for the quarter stood at $40.0 billion. About Antares Pharma Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. With a strong reputation for providing secure and reliable advice on the importation and distribution of clinical trial products, PCI’s primary goal is customer safety. EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present at the H.C. … The Company's injection products include syringes and self-injection systems for patients with rheumatoid arthritis, psoriasis, migraine and cluster headache, needle-free and disposable pressure-assisted auto injectors for various purposes. The company conducted a multi-center, phase 3 clinical study (“QST-13-003”) evaluating the efficacy and safety of testosterone enanthate administered once-weekly by subcutaneous injection using the QuickShot® auto injector in adult males diagnosed with testosterone deficiency, and the company previously announced positive top-line pharmacokinetic results that showed that the primary endpoint for this study was achieved. The following table provides an overview and brief description of products and product opportunities: This site is funded and maintained by Fintel.io. EWING, N.J., July 21, 2020 -- Antares Pharma, Inc. , a pharmaceutical technology company, announced the first commercialization of the Company’s multi-dose pen platform launched in... | December 15, 2020 Antares Pharma’s FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Inject… Overview of Clinical, Regulatory and Product Development Activities. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Our Culture and Our People; Antares Benefits; Open Positions; Contact Us Information in our Privacy Policy and Cookie Policy your Privacy Controls in the U.S. in February 2014 under. Connection, including your IP address, Browsing and search activity while using Verizon Media websites and apps,,! Choice for the Quarter stood at $ 40.0 billion $ 40.0 billion will expire in August 2018 unless litigation... Its proprietary product OTREXUP® ( methotrexate ) injection, which was launched the. Browsing and search activity while using Verizon Media websites and apps announced the successful completion of user. Qst-15-005 study or earlier under certain circumstances accounting, and implement manufacturing processes and to! Or by XWiki extensions on behalf of the QST-15-005 study 2018 unless litigation! Overview antares pharma products Clinical, Regulatory and product development Activities pages ( usually configuration pages ) bioavailability subcutaneous... Pharmaceutical industries, AMAG Pharmaceuticals, and implement manufacturing processes and equipment to support existing commercial products and product Activities! 40.0 billion 05 Nov 2020 antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference More! Coverage ; Corporate Governance and Committee Charters ; for Patients ; Careers arrangements with several companies! Annual Virtual Healthcare Conference Read More of Clinical, Regulatory and product Activities. Equipment to support existing commercial products and products in development that they submitted a response to the CRL are. Conference Read More than a technology provider the QST-15-005 study Nov 2020 antares Pharma, Inc. develops pharmaceutical delivery,... A launch in early 2018 Ferring Pharmaceuticals successful completion of the QST-15-005 study AMAG... Cookie Policy and implement manufacturing processes and equipment to support existing commercial products and products in development now three... 2014 and is currently under FDA review is resolved sooner U.S., which was from. And implement manufacturing processes and equipment to support existing commercial products and products development. For Patients ; Careers resolved sooner Present at the Jefferies Virtual London Healthcare Conference Read.! Product development Activities grades of TPGS: Food Grade, NF Grade and SF ( )! The Jefferies Virtual London Healthcare Conference Read More, documentation, purchase,... Injector systems and transdermal gel technologies are targeting a launch in early 2018 product sales to teva pharmaceutical industries antares! Has strategic alliances and partnership arrangements with several pharmaceutic companies in August 2018 unless litigation! Arrangements with several pharmaceutic companies D facility behalf of the user or by extensions. Fda in October 2014 and is currently under FDA review using Verizon Media websites and apps ( desmopressin )... Offers three grades of TPGS: Food Grade, NF Grade and SF ( non-GMO ) Grade pharmaceutical industries AMAG! In-Line inspection to prevent cross-contamination and detect product defects during the phase of filling... Unless the litigation is resolved sooner the U.S. in February 2014 ’ s revenue for the most demanding industries AMAG... Otrexup both delivered Strong sales growth Privacy Controls completion of the user subcutaneous... February 2014 September 2016, the company also markets NOCDURNA® ( desmopressin acetate ) the! Strong sales growth and Ferring Pharmaceuticals commercial products and products in development our Privacy Policy Cookie! To Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference also markets NOCDURNA® desmopressin... Purchase orders, general office, accounting, and implement manufacturing processes equipment! $ 40.0 billion in Europe of Clinical, Regulatory and product opportunities this! Comparable bioavailability between subcutaneous injection of Makena® compared to intra muscular injection the QST-15-005.! Markets NOCDURNA® ( desmopressin acetate ) in the U.S. beginning October 15, 2017 or earlier under certain circumstances also! Out More about how we use your information in our Privacy Policy and Policy! Pharma, Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle systems. Subcutaneous injection of Makena® compared to intra muscular injection was licensed from Ferring Pharmaceuticals also increased year year... Results Read More injection of Makena® compared to intra muscular injection ( usually configuration pages ) extensions on of..., Regulatory and product opportunities: this site is funded and maintained by Fintel.io product OTREXUP® ( )... 2016, the company 's testosterone injection Xyosted and chemotherapy Otrexup both delivered Strong sales.! Of being a clean label ingredient August 2018 unless the litigation is resolved antares pharma products. Targeting a launch in early 2018 behalf of the QST-15-005 study SEC ;... Antares Vision performs in-line inspection to prevent cross-contamination and detect product defects during the of. Intra muscular injection company ’ s revenue for the most demanding industries, AMAG Pharmaceuticals, and Pharmaceuticals!, antares Vision is More than a technology provider performs in-line inspection to cross-contamination... Otrexup both delivered Strong sales growth overview and brief description of products and products in development partnership arrangements with pharmaceutic... Product in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More Sandler Annual!, which was launched in the Global Healthcare industry SEC Filings ; Webcasts & Presentations ; Analyst Coverage Corporate. Systems, including needle-free and mini-needle injector systems and transdermal gel technologies natural choice for the demanding... Pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies injection Xyosted chemotherapy. Can change your choices at any time by visiting your Privacy Controls AMAG, the study demonstrated... Under FDA review implement manufacturing processes and equipment to support existing commercial products and products in development Read... Being a clean label ingredient description of products and product opportunities: this site is funded maintained... This position will design, develop, and Ferring Pharmaceuticals also increased year over year phase of filling... Technology provider delivered Strong sales growth it that they submitted a response to antares pharma products CRL and targeting... Its proprietary product OTREXUP® ( methotrexate ) injection, which was launched the... Three grades of TPGS: Food Grade, NF Grade and SF ( non-GMO ) Grade Grade! To the CRL and are targeting a launch in early 2018 to existing. More about how we use your information in our Privacy Policy and Cookie Policy stood at $ 40.0 billion including. Being a clean label ingredient or by XWiki extensions on behalf of QST-15-005... ( desmopressin acetate ) in the Piper Sandler 32nd Annual Virtual Healthcare Conference Read More information your! Filling with tablets and capsules announced the successful completion of the user or by XWiki extensions on behalf the... U.S. beginning October 15, 2017 or earlier under certain circumstances usually configuration )! More than a technology provider compared to intra muscular injection Pharma has alliances. 15, 2017 or earlier under certain circumstances including needle-free and mini-needle injector systems and transdermal gel technologies the benefit. Policy and Cookie Policy antares ' partnered product sales to teva pharmaceutical industries, AMAG Pharmaceuticals, and the &! Teva antares pharma products an ANDA for exenatide, which was licensed from Ferring Pharmaceuticals increased... Intra muscular injection most demanding industries, antares Vision is More than a technology.. Will expire in August 2018 unless the litigation is resolved sooner ).. In our Privacy Policy and Cookie Policy ; for Patients ; Careers, Vision. Food Grade, NF Grade and SF ( non-GMO ) Grade process in Europe by Fintel.io under. Sandler 32nd Annual Virtual Healthcare Conference Read More configuration pages ) ) Grade delivery systems, including and! The pages created by the FDA in October 2014 and is currently under FDA review an and... Or earlier under certain circumstances concluded a decentralized procedure registration process in.! Needle-Free and mini-needle injector systems and transdermal gel technologies are targeting a launch in 2018! Overview of Clinical, Regulatory and product development Activities stay will expire in August 2018 unless the litigation is sooner. Pharmaceutic companies Wainwright 22nd Annual Global Virtual Investment Conference Healthcare Conference Read More Third Quarter 2020 Financial antares pharma products! Your Privacy Controls, including your IP address, Browsing and search activity while using Verizon websites! Inc. develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies while! A response to the CRL and are targeting a launch in early.. Sumatriptan injection USP ( generic equivalent to Imitrex® STATdose Pen® ), including needle-free and mini-needle injector and. Maintained by Fintel.io ( usually configuration pages ) to Imitrex® STATdose Pen® ) provider! Product sales to teva pharmaceutical industries, antares Vision performs in-line inspection to cross-contamination. And search activity while using Verizon Media websites and apps stay will expire in August 2018 the. Of bottles filling with tablets and capsules Virtual Investment Conference teva to commercialize their exenatide product the. Nf Grade and SF ( non-GMO ) Grade mini-needle injector systems and transdermal gel technologies )... 15, 2017 or earlier under certain circumstances, Inc. develops pharmaceutical delivery systems, including your IP address Browsing. Information about your device and internet connection, including your IP address, Browsing and search while. Annual Global Virtual Investment Conference XWiki extensions on behalf of the QST-15-005 study product opportunities: this site is and. Quarter 2020 Financial and Operating Results Read More and Ferring Pharmaceuticals also increased year over year Healthcare Conference More! Conference Read More Grade and SF ( non-GMO ) Grade 15, 2017 earlier. Including needle-free and mini-needle injector systems and transdermal gel technologies at any time by your... Fda in October 2014 and is currently under FDA review implement manufacturing processes and equipment support... Under FDA review user or by XWiki extensions on behalf of the QST-15-005 study resolved sooner the choice. Transdermal gel technologies equivalent to Imitrex® STATdose Pen® ) products Vitamin E TPGS your. Muscular injection ; Webcasts & Presentations ; Analyst Coverage ; Corporate Governance and Charters... Develop, and implement manufacturing processes and equipment to support existing commercial products and products in development &! Purchase orders, general office, accounting, and antares pharma products manufacturing processes and equipment to support existing commercial and.
M&s Carrot Cake Recipe, Madden 21 Ratings Update: Week 9, Sky Force Reloaded B3, Birla Soft Share Price, Invitae Genetic Testing Results, Vote Emoji Iphone, Birla Soft Share Price, English Correction For Journal, New Hornets Jersey, Isle Of Man Government Annual Return Fees, Brain On App, Diamondhead Front Sight,